Biotech Values

[RockRat]

>>EMIS’ CEO says some unflattering things about MNTA, by the way, but I guess that's not surprising.<<

Do tell. I like MNTA, so I'd be interested in a competitor's bear case as a check. Actually, I had forgotten about EMIS' oral heparins, can I trouble you to summarize their current status?

Anybody think GNBT's buccal delivery system is viable? Seems to have the advantage of avoiding pulmonary safety issues that dog inhaled insulin. But not sure if it works as advertised, or that some pulmonary delivery doesn't occur, anyway, since it is sprayed into the mouth.

TIA & Regards, RockRat